x

Intellia Therapeutics and Regeneron Pharmaceuticals have announced a licensing and collaboration agreement to advance CRISPR/Cas gene editing technology for in vivo therapeutic development. In addition to the discovery, development and commercialization of new therapies, the companies will focus on technology development of the CRISPR/Cas platform. Read More..

Intellia

CRISPR/Cas9 Gene-Editing Technology: The Therapeutic Revolution Has Begun

Imagine being able to remove or change any DNA mutation to cure cystic fibrosis or sickle cell disease. Or to easily delete, insert or repair genes and effect one-time curative treatments for diseases of the liver and blood, and cancer.
That is the power of CRISPR/Cas9 gene editing, which the MIT Technology Review called “the biggest biotech discovery of the century.” Intellia Therapeutics has the vision, leadership and strategy to fully realize CRISPR/Cas9’s unprecedented potential to deliver life-changing curative medicines to millions of people worldwide.

Intellia

Curative Medicines for Multiple Diseases

CRISPR/Cas9 is a powerful and precise, yet simple, tool for developing curative medicines for intractable and life-threatening genetic diseases.

Learn More
Intellia

Big Plans

CRISPR/Cas9 inspires us to think big and move fast. We are pursuing several opportunities simultaneously with a single purpose: To create curative medicines for patients who need them the most.

Learn More
Intellia

eXtellia complements Intellia’s five-year collaboration with Novartis, announced in January, 2015, which is focused on CRISPR/Cas9 applications with chimeric antigen receptor T-cells (CART)- and Hematopoietic Stem Cell (HSC)-based therapies. Intellia scientists will continue to work closely with Novartis. eXtellia scientists intend to leverage the potential of CRISPR/Cas9 across a variety of immune cells, such as natural killer cells and T-cells, to develop therapies for patients where treatments needs are inadequately addressed. Read More..

Meet The Team
What does Intellia and CRISPR/Cas9 mean to you?